Rapcabtagene autoleucel

Unknown / undisclosed

Also known as YTB323

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Lupus Nephritis
NCT06581198 · Novartis Pharmaceuticals
2024-09-04 – 2032-02-06 · Lupus Erythematosus, Systemic, Lupus Nephritis
What this study did
Other / comorbidity
NCT06665256 · Novartis Pharmaceuticals
2024-12-17 – 2032-11-29 · Idiopathic Inflammatory Myopathies
What this study did
NCT06655896 · Novartis Pharmaceuticals
2024-10-29 – 2032-08-30 · Scleroderma, Diffuse
What this study did
NCT06868290 · Novartis Pharmaceuticals
2025-03-13 – 2030-05-24 · ANCA Associated Vasculitis (AAV)
What this study did
Phase 1/2 (6)
Lupus Nephritis
NCT05798117 · Novartis Pharmaceuticals
2023-02-28 – 2026-09-24 · Systemic Lupus Erythematosus, Lupus Nephritis
What this study did
Other / comorbidity
NCT06617793 · Novartis Pharmaceuticals
2025-02-24 – 2030-08-07 · Relapsing Multiple Sclerosis
What this study did
NCT06675864 · Novartis Pharmaceuticals
2024-12-12 – 2030-06-14 · Progressive Multiple Sclerosis
What this study did
NCT06704269 · Novartis Pharmaceuticals
2025-04-22 – 2029-10-26 · Generalized Myasthenia Gravis
What this study did
NCT07048197 · Novartis Pharmaceuticals
2025-06-20 – 2028-11-01 · Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
What this study did
NCT03960840 · Novartis Pharmaceuticals
2019-06-26 – 2027-07-24 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
What this study did
Phase 1 (1)
Other / comorbidity
NCT07443137 · Stanford University
2026-09-15 – 2028-08 · Large-cell Lymphoma
What this study did

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, 3 of them ahead of this one.

This drug's own stage for Lupus Nephritis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rapcabtagene Autoleucel: this drugPhase 2UndisclosedCD19not yet gradedNo reviewed efficacy summary in this indication
Belimumab (GSK1550188) (Benlysta)ApprovedMonoclonal antibodyBAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS)Reliable signalNo reviewed efficacy summary in this indication
Inebilizumab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ObinutuzumabApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tafasitamab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Voclosporin (Lupkynis)ApprovedSmall moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)Reliable signal
NCT03021499: Number of Participants With Adjudicated Renal Response at Week 52 (52 Weeks): Voclosporin — Number of renal responders: 73/179 (40.8%); Number of renal non-responders: 106/179 (59.2%) vs Placebo Oral Capsule — Number of renal responders: 40/178 (22.5%); Number of renal non-responders: 138/178 (77.5%)
Budoprutug
Phase 2(overall)
Monoclonal antibodyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Ebribafusp AlfaPhase 2Protein / enzyme therapeuticC3d / Factor Hnot yet gradedNo reviewed efficacy summary in this indication
FT819
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
SHR-2173Phase 2UndisclosedIFNAR1 / TACInot yet gradedNo reviewed efficacy summary in this indication
Beijing Biotech Anti-CD19 CAR-T
Phase 1/2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Zugocabtagene Geleucel
Phase 1/2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-319
Phase 1(overall)
Antibody–drug conjugateCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-519
Phase 1(overall)
—CD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
IC19 CAR-T
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
UTAA09
Phase 1(overall)
Cell therapyCD19
Weak signal(overall)
No reviewed efficacy summary in this indication
VonsetamigPhase 1—BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
ZM001
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT522
—(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Vispacabtagene Regedleucel
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rapcabtagene autoleucel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 1/2Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT03960840 · CT.gov ↗
What to watch
2028 (4)
February 2028 (1)
Phase 2Lupus NephritisActive not recruiting
Est. primary completion 2028-02-14 · NCT06581198 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Large-cell LymphomaRecruiting
Est. primary completion 2028-08 · NCT07443137 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1/2Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)Active not recruiting
Est. primary completion 2028-11-01 · NCT07048197 · CT.gov ↗
What to watch
Phase 2Scleroderma, DiffuseActive not recruiting
Est. primary completion 2028-11-30 · NCT06655896 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
Phase 2Idiopathic Inflammatory MyopathiesActive not recruiting
Est. primary completion 2029-03-09 · NCT06665256 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2ANCA Associated Vasculitis (AAV)Active not recruiting
Est. primary completion 2029-06-07 · NCT06868290 · CT.gov ↗
What to watch
October 2029 (1)
Phase 1/2Generalized Myasthenia GravisActive not recruiting
Est. primary completion 2029-10-26 · NCT06704269 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 1/2Progressive Multiple SclerosisActive not recruiting
Est. primary completion 2030-06-14 · NCT06675864 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1/2Relapsing Multiple SclerosisActive not recruiting
Est. primary completion 2030-08-07 · NCT06617793 · CT.gov ↗
What to watch

See the full readout calendar ↗